Literature DB >> 11306601

Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

J W Knowles1, G Esposito, L Mao, J R Hagaman, J E Fox, O Smithies, H A Rockman, N Maeda.   

Abstract

Mice lacking natriuretic peptide receptor A (NPRA) have marked cardiac hypertrophy and chamber dilatation disproportionate to their increased blood pressure (BP), suggesting, in support of previous in vitro data, that the NPRA system moderates the cardiac response to hypertrophic stimuli. Here, we have followed the changes in cardiac function in response to altered mechanical load on the heart of NPRA-null mice (Npr1-/-). Chronic treatment with either enalapril, furosemide, hydralazine, or losartan were all effective in reducing and maintaining BP at normal levels without affecting heart weight/body weight. In the reverse direction, we used transverse aortic constriction (TAC) to induce pressure overload. In the Npr1-/- mice, TAC resulted in a 15-fold increase in atrial natriuretic peptide (ANP) expression, a 55% increase in left ventricular weight/body weight (LV/BW), dilatation of the LV, and significant decline in cardiac function. In contrast, banded Npr1+/+ mice showed only a threefold increase in ANP expression, an 11% increase in LV/BW, a 0.2 mm decrease in LV end diastolic dimension, and no change in fractional shortening. The activation of mitogen-activated protein kinases that occurs in response to TAC did not differ in the Npr1+/+ and Npr1-/- mice. Taken together, these results suggest that the NPRA system has direct antihypertrophic actions in the heart, independent of its role in BP control.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306601      PMCID: PMC199554          DOI: 10.1172/JCI11273

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

Review 1.  ABC of heart failure. Pathophysiology.

Authors:  G Jackson; C R Gibbs; M K Davies; G Y Lip
Journal:  BMJ       Date:  2000-01-15

2.  Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes.

Authors:  T Horio; T Nishikimi; F Yoshihara; H Matsuo; S Takishita; K Kangawa
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

3.  Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload.

Authors:  G Esposito; S V Prasad; A Rapacciuolo; L Mao; W J Koch; H A Rockman
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

4.  Cardiac fibrosis in mice lacking brain natriuretic peptide.

Authors:  N Tamura; Y Ogawa; H Chusho; K Nakamura; K Nakao; M Suda; M Kasahara; R Hashimoto; G Katsuura; M Mukoyama; H Itoh; Y Saito; I Tanaka; H Otani; M Katsuki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 5.  Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans.

Authors:  A Clerico; G Iervasi; G Mariani
Journal:  Horm Metab Res       Date:  1999-09       Impact factor: 2.936

6.  Cardiac hypertrophy: old concepts, new perspectives.

Authors:  M Gupta; M P Gupta
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

7.  Cellular and functional defects in a mouse model of heart failure.

Authors:  G Esposito; L F Santana; K Dilly; J D Cruz; L Mao; W J Lederer; H A Rockman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-12       Impact factor: 4.733

8.  Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.

Authors:  J E Bishop; L A Kiernan; H E Montgomery; P Gohlke; J R McEwan
Journal:  Cardiovasc Res       Date:  2000-07       Impact factor: 10.787

9.  A genetic model defines the importance of the atrial natriuretic peptide receptor (guanylyl cyclase-A) in the regulation of kidney function.

Authors:  S K Dubois; I Kishimoto; T O Lillis; D L Garbers
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

10.  Cardiac hypertrophy and antihypertensive therapy.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Cardiovasc Res       Date:  1977-09       Impact factor: 10.787

View more
  93 in total

1.  Natriuretic peptide receptors and the heart.

Authors:  L King; M R Wilkins
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

2.  A friend within the heart: natriuretic peptide receptor signaling.

Authors:  Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 3.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 4.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

5.  Altered expression of the natriuretic peptide system in genetically modified heme oxygenase-1 mice treated with high dietary salt.

Authors:  David W J Armstrong; M Yat Tse; Luis G Melo; Stephen C Pang
Journal:  Mol Cell Biochem       Date:  2010-09-25       Impact factor: 3.396

6.  Divergence of hypertrophic growth and fetal gene profile: the influence of beta-blockers.

Authors:  X-J Du
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 7.  Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.

Authors:  Kailash N Pandey
Journal:  Can J Physiol Pharmacol       Date:  2011-08-04       Impact factor: 2.273

8.  Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis.

Authors:  Leigh J Ellmers; J W Knowles; H-S Kim; O Smithies; N Maeda; V A Cameron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08       Impact factor: 4.733

9.  Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity.

Authors:  Wei Wang; Xudong Liao; Koichi Fukuda; Sabine Knappe; Faye Wu; Daniel L Dries; Jun Qin; Qingyu Wu
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

10.  Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development.

Authors:  Nicola J A Scott; Leigh J Ellmers; John G Lainchbury; Nobuyo Maeda; Oliver Smithies; A Mark Richards; Vicky A Cameron
Journal:  Biochim Biophys Acta       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.